CMS Cancer "Quality Of Care" Data Show "A Lot Of Variations," McClellan Says
This article was originally published in The Pink Sheet Daily
Preliminary data from the oncology demonstration project show variable quality-of-life outcomes, likely because many patients have late-stage cancer, CMS Administrator McClellan says. The program may ultimately help drive improvements in clinical practices, he predicts.
You may also be interested in...
“As each day goes by, we feel better” about ASP-based reimbursement for Medicare Part B drugs, CEO Sharer says. CMS’ “quality of care” demonstration project helps Amgen’s first quarter performance, resulting in increased guidance for 2005. Company execs predict the demo program will continue into 2006 due to “strong lobbying.”
The Medicare program is earmarking $300 mil. for a "quality of care" demonstration project that should help smooth the transition to ASP-based reimbursement in 2005
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.